Review of Contemporary Philosophy
ISSN: 1841-5261, e-ISSN: 2471-089X
Vol 23 (2), 2024
Pp 6692 - 6702

Atherosclerosis: An Updated Overview for Healthcare Providers

[1]- Abdulaziz Ali Alqahtani ,[2]- Mouth Mohammad Bin Naji,[3]-Ahmad Mohamed Al-Mutairi,[4]- Yasser Khalid Munif Alotaibi,[5]- Faraj Mohammed Shwaim,[6]- Rahab Waealan Bakari,[7]- Naif Motlaq Alrowaidan,[8]-Abdullah Mohammed Ali Alsalman

[1] Ksa, Ministry Of Health, Riyadh Third Health Cluster
[2] Ksa, Ministry Of Health, Riyadh Third Health Cluster|
[3] Ksa, Ministry Of Health, Sajer General Hospital
[4] Ksa, Ministry Of Health, Al-Rifaya Hospital In Jamsh
[5] Ksa, Ministry Of Health, Al Rawda Health Center In Aflaj
[6] Ksa, Ministry Of Health, Al-Eidabi General Hospital
[7] Ksa, Ministry Of Health, Medical Supplies
[8] Ksa, Ministry Of Health, King Fahad Hofuf Hospital

Abstract:

Background: Atherosclerosis is a chronic inflammatory disease of the arteries, driven by lipid accumulation and inflammatory processes, leading to plaque formation and subsequent cardiovascular events such as heart attacks and strokes. It is the leading cause of death in industrialized societies, accounting for approximately 50% of fatalities. Risk factors include hypercholesterolemia, hypertension, diabetes, smoking, and lifestyle factors like physical inactivity and poor diet. The disease progresses from fatty streaks to advanced plaques, which can rupture or erode, causing acute cardiovascular events.

Aim: This review aims to provide an updated overview of the pathophysiology, risk factors, diagnostic approaches, and management strategies for atherosclerosis, emphasizing the importance of understanding its molecular and cellular mechanisms to develop effective therapeutic interventions.

Methods: The review synthesizes current knowledge on the etiology, epidemiology, and pathophysiology of atherosclerosis. It discusses diagnostic tools such as lipid profiling, imaging techniques (e.g., CT angiography, calcium scoring), and clinical evaluations. Management strategies, including lifestyle modifications, pharmacological treatments (e.g., statins, antihypertensives), and surgical interventions (e.g., revascularization), are also examined.

Results: Atherosclerosis progresses through stages, from early fatty streaks to advanced plaques prone to rupture. Diagnostic advancements, such as non-invasive imaging and biomarkers, have improved early detection and risk stratification. Effective management involves controlling modifiable risk factors through lifestyle changes and medications, significantly reducing the risk of cardiovascular events. However, advanced disease with end-organ damage remains challenging to treat.

Conclusion: Atherosclerosis is a complex, multifactorial disease that requires a comprehensive approach to prevention, diagnosis, and management. Early intervention through lifestyle changes and pharmacological therapy can significantly improve outcomes. Continued research into its pathophysiology and innovative diagnostic tools is essential for further reducing the global burden of atherosclerotic cardiovascular disease.

Keywords: Atherosclerosis, cardiovascular disease, plaque rupture, LDL cholesterol, inflammation, statins, imaging, risk factors, management.

Received: 10 October 2024 **Revised**: 22 November 2024 **Accepted:** 05 December 2024

Introduction:

Atherosclerosis is a long-term inflammatory disorder that primarily affects the arteries, and it is responsible for approximately 50% of deaths in industrialized societies. This disease is predominantly lipid-driven, beginning with the buildup of low-density lipoproteins (LDL) and remnant lipoproteins within the arterial walls. These lipid particles initiate an inflammatory response in specific areas of the arteries, particularly at points where blood flow becomes disturbed, such as at branch points or areas with turbulent flow. These regions are particularly vulnerable to the onset of atherosclerosis due to the altered hemodynamic conditions that promote the accumulation of lipid particles and the activation of inflammatory processes. As the disease progresses, it leads to the formation of atherosclerotic plaques, which can cause significant narrowing and stiffening of the arteries. Atherosclerosis is considered the primary underlying cause of atherosclerotic cardiovascular disease (ASCVD), which includes conditions such as heart attacks, strokes, and peripheral arterial disease. These outcomes result from the obstruction or rupture of the atherosclerotic plaques, leading to impaired blood flow and organ damage. The pathophysiology of atherosclerosis involves complex interactions between lipids, inflammatory cells, and the endothelial lining of blood vessels, contributing to both the initiation and progression of the disease. In this review, we aim to examine the vascular biology that underpins the development of atherosclerosis, the sequelae that arise from the disease, and potential strategies for its management. Understanding the molecular and cellular mechanisms involved is crucial for identifying novel therapeutic approaches to reduce the burden of ASCVD [1][2][3].

Etiology:

Atherosclerotic cardiovascular disease (ASCVD) arises from a combination of multiple factors. Key risk elements include hypercholesterolemia, particularly elevated low-density lipoprotein (LDL)-cholesterol levels, hypertension, diabetes mellitus, smoking, and advancing age. Men older than 45 years and women over 55 years are at higher risk, with male gender itself being a contributing factor. Additionally, a family history of ASCVD in male relatives younger than 55 years or female relatives younger than 65 years significantly increases risk. Lifestyle factors such as physical inactivity, obesity, and diets rich in saturated and trans fats also contribute to the development of ASCVD. Furthermore, genetic factors, including certain mutations, play a role in susceptibility to the disease. Although low levels of high-density lipoprotein (HDL)-cholesterol are commonly viewed as a risk factor for ASCVD, attempts to increase HDL-cholesterol through pharmacological interventions have generally been ineffective. This raises doubts about the protective role of HDL in the pathogenesis of ASCVD. Despite its traditionally recognized role in cholesterol transport, recent findings challenge its direct involvement in preventing or mitigating the disease process. Therefore, while low HDL levels remain a concern, the exact mechanisms linking HDL to ASCVD risk are still under investigation [4][5][6].

Epidemiology:

Atherosclerosis is largely asymptomatic in its early stages, making it difficult to accurately determine its incidence. However, it is widely regarded as the primary cause of cardiovascular diseases, particularly ischemic heart disease (IHD) and ischemic stroke. IHD and stroke are the leading causes of death globally, ranked first and fifth, respectively [7][8][9][10]. In the United States, heart disease is responsible for approximately 610,000 deaths annually, accounting for one in every four deaths. Coronary heart disease alone claims over 370,000 lives each year, making it the leading cause of death in the Western world. Annually, around 735,000 Americans experience a heart attack, with 525,000 being first-time incidents and 210,000 representing recurrent attacks. It has been reported that 75% of acute myocardial infarctions are triggered by plaque rupture, with the highest frequency of such ruptures occurring in men over 45 years of age. In women, the incidence of plaque rupture rises after the age of 50. The higher prevalence of atherosclerosis in men compared to women is generally attributed to the protective effects of female sex hormones, which diminish after menopause. Stroke, irrespective of its cause, ranks as the fifth leading cause of death and remains the leading cause of severe long-term disability in adults in the United States. Approximately 795,000 people suffer a stroke each year, with about 140,323 deaths resulting from these events. Ischemic stroke, which is the most common type, is largely caused by ASCVD. Numerous epidemiologic studies conducted in North America and Europe have identified a range of risk factors for the onset and progression of atherosclerosis. These factors influence the development of atherosclerosis by affecting low-density lipoprotein (LDL) particles and promoting inflammatory processes [7][8][9][10].



Figure 1: Atherosclerosis.

Pathophysiology:

Atherosclerosis is a progressive, multifactorial disease characterized by the accumulation of lipids, inflammatory cells, and fibrous tissue in the arterial walls, leading to the formation of plaques that can obstruct blood flow. It primarily begins as lipid retention within the arterial intima, where lipoproteins, especially low-density lipoproteins (LDL), are trapped by matrix components such as proteoglycans. These modified lipoproteins trigger chronic inflammation, which plays a crucial role in the initiation and progression of atherosclerosis. The pathophysiological changes occur in stages, starting from nascent fatty streaks in the intima, which evolve into fibrous plaques and eventually become complex atherosclerotic lesions. Over time, these lesions become prone to rupture, leading to catastrophic events like myocardial infarction or stroke. Stenosis resulting from inward plaque expansion can also lead to vessel occlusion, particularly in the coronary arteries, though the impact of these blockages can be mitigated by the formation of collateral circulation. Systemic changes in atherosclerosis are relatively uniform across different arterial regions, including the aorta, coronary arteries, and carotid arteries. This disease is often described as a series of histological developments, with different stages of lesion formation visible to the naked eye. These stages provide insight into the dynamic nature of the disease and the role of various molecular and cellular mechanisms in its progression.

Staging:

The development of atherosclerosis occurs in several distinct stages, each with its characteristic histologic features. The major phases of atherosclerosis development are as follows:

Early Fatty Streak Phase

The fatty streak phase begins in childhood, with the earliest signs of atherosclerosis observed in the form of adaptive intimal thickening. This process occurs from birth and is often most pronounced in areas exposed to high oscillatory shear stress, typically seen at arterial branch points. In these areas, lipoproteins, particularly modified LDL particles, are retained in the intima. The retention of these lipoproteins is facilitated by matrix components such as proteoglycans, which trap the lipoproteins and lead to their modification. Modified LDL is a critical factor in the development of atherosclerosis, although the precise mechanisms behind LDL modification are not fully understood. Oxidation of LDL particles, which generates oxidized LDL, is often considered a key modification. Modified LDL particles are recognized by scavenger receptors, such as SRA and CD36, which facilitate their uptake by endothelial cells and smooth muscle cells. This results in the formation of foam cells—macrophages that accumulate lipid material. Foam cell formation is a hallmark of the early fatty streak lesion. Endothelial dysfunction plays a central role in the development of early fatty streaks. Factors like high levels of LDL, smoking, diabetes, and hypertension contribute to endothelial injury by reducing the availability of nitric oxide (NO) and prostacyclin. These molecules typically promote vasodilation and inhibit platelet aggregation and inflammation. The reduction in NO and prostacyclin, along with an increase in plasminogen activator inhibitor type 1 (PAI-1), increases endothelial cell adhesion and promotes the recruitment of immune cells, including monocytes and lymphocytes, to the site of injury. Endothelial dysfunction can also lead to increased permeability of the endothelial barrier, allowing the transendothelial migration of immune cells and atherogenic lipoproteins into the intima. As the monocytes accumulate in the intima, they differentiate into macrophages under the influence of macrophage colony-stimulating factor (M-CSF), which then engulf modified lipids and become foam cells, a defining feature of the early fatty streak.

Early Fibroatheroma Phase

As foam cells accumulate, the next phase of atherosclerosis involves the migration of smooth muscle cells (SMCs) from the media into the intima. This migration is primarily driven by a variety of growth factors, including angiotensin II, platelet-derived growth factor (PDGF), and insulin-like growth factor (IGF). These smooth muscle cells are essential for the formation of the fibrous cap, which forms over the lipid core of the plaque. The fibrous cap is primarily composed of collagen and other extracellular matrix proteins and serves as a protective barrier that prevents plaque rupture. However, as the fibrous cap thickens, the plaque becomes increasingly prone to destabilization, particularly under conditions of high shear stress or ongoing inflammation. In this phase, lymphocytes, particularly type-1 and type-2 T-helper cells (TH1 and TH2), also play a significant role in plaque formation. The inflammatory response in the plaque is further augmented by the release of cytokines such as interleukin-1 (IL-1) and chemokines like monocyte chemoattractant protein-1 (MCP-1), which recruit additional inflammatory cells to the site of injury. Cell adhesion molecules (CAMs), such as vascular cell adhesion molecule 1 (VCAM-1) and P-selectin, facilitate the adhesion of these immune cells to the endothelial surface. The activation of the CD40-CD40 ligand (CD40L) dyad also contributes to the inflammatory environment, enhancing the immune response and promoting the progression of atherosclerosis.

Smooth muscle cell migration and proliferation, along with the accumulation of extracellular matrix proteins, result in the formation of the fibrous plaque. This phase is characterized by the development of a more organized plaque, with both lipid and fibrous components, providing a greater degree of structural stability. The fibrous plaque serves as a protective shield, limiting the exposure of the arterial wall to the atherogenic lipoproteins and immune cells. However, the plaque remains vulnerable to rupture due to ongoing inflammation, mechanical stress, and the destabilizing effects of the lipid-rich core. The pathophysiology of atherosclerosis is complex and involves a series of histological changes and cellular interactions that occur over time. The early fatty streak phase marks the initial stage of lipid accumulation and foam cell formation, while the progression to fibrous plaques introduces structural changes that aim to protect the vessel wall from rupture. However, this protective mechanism is not foolproof, and the continuous inflammatory process ultimately leads to plaque instability. Understanding the molecular and cellular mechanisms involved in atherosclerosis is essential for developing effective treatments and preventive strategies to combat this prevalent and life-threatening disease.

Advanced Atheroma: Thin-Cap Fibroatheroma and Its Rupture

The progression of atherosclerotic plaques, particularly those with a thin fibrous cap, is critical in the pathogenesis of major cardiovascular events. As individuals age, typically between 55 to 65 years, advancing atheroma or vulnerable plaques develop, with these thin-cap fibroatheromas becoming the most dangerous forms of atherosclerotic lesions. These lesions are characterized by a fibrous cap that is relatively thin and weak, a lipid-rich necrotic core, and a substantial presence of inflammatory cells such as macrophages. The fibrous cap of vulnerable plaques is often composed of low-density smooth muscle cells

(SMCs) and is highly susceptible to mechanical stress, chemical modification, and proteolytic degradation. Matrix metalloproteinases (MMPs) and other proteolytic enzymes produced by infiltrating inflammatory cells weaken the fibrous cap, making it prone to rupture. The rupture of the plaque exposes the underlying necrotic core to the bloodstream, triggering a cascade of events that results in the formation of a thrombus. This thrombus can significantly reduce or completely obstruct blood flow, leading to life-threatening conditions like myocardial infarction (MI) or ischemic stroke. The necrotic core, which consists of cholesterol-enriched macrophages, cholesterol crystals, and T lymphocytes, plays a key role in plaque vulnerability. The lipid content of the necrotic core, alongside the abundant macrophages, contributes to the inflammatory environment within the plaque. Macrophages are particularly important in plaque destabilization due to their secretion of pro-inflammatory cytokines and enzymes like MMPs, which degrade the extracellular matrix and facilitate fibrous cap thinning. Additionally, the presence of tissue factor in the macrophages and other cells within the plaque promotes thrombosis upon rupture.

Plaque Rupture

Plaque rupture is the leading cause of acute cardiovascular events. Rupture typically occurs in the fibrous cap, where the exposed necrotic core interacts with circulating blood, triggering the formation of a thrombus. The left anterior descending (LAD) coronary artery, a critical artery supplying the heart, is the most common site for plaque rupture, followed by the left and right circumflex coronary arteries. While the exact causes of plaque rupture remain poorly understood, several factors have been implicated. These include the expression of proteolytic enzymes, such as MMPs, produced by inflammatory cells within the plaque, as well as factors like macrophage calcification, iron deposition, and the mechanical forces exerted on plaques in high-shear arterial regions. Enzymatic activity, particularly by MMPs and myeloperoxidase (produced by activated inflammatory cells), can degrade the fibrous cap, destabilizing the plaque. Other contributing factors include hemodynamic stress due to high blood flow velocity, which can also contribute to cap rupture. This process of rupture is exacerbated by a dysregulated balance of proteolytic and anti-proteolytic factors within the plaque, as well as changes in smooth muscle cell content and the loss of protective collagen in the fibrous cap.

Growth and Development of the Necrotic Core

The necrotic core is a hallmark of advanced atherosclerotic plaques and contributes significantly to their instability. The expansion of the necrotic core is driven by the accumulation of dead cells, particularly macrophages that undergo apoptosis within the plaque. Studies have shown that intraplaque hemorrhage, which occurs when microvessels within the plaque rupture and leak blood into the lesion, accelerates necrotic core expansion. The red blood cells from these hemorrhages contain lipids and cholesterol, both of which contribute to the accumulation of free cholesterol in the plaque and further promote plaque rupture. The endoplasmic reticulum (ER) stress pathway has also been implicated in macrophage death within plaques, contributing to the expansion of the necrotic core. ER stress, particularly the unfolded protein response (UPR), is believed to drive cellular apoptosis in plaque macrophages. In addition to macrophage death, defective phagocytosis and inefficient clearance of apoptotic cells contribute to the accumulation of dead macrophages within the plaque. As necrotic material accumulates, the microvessel density within the plaque increases, a phenomenon known as dysregulated neovascularization. These newly formed vessels, however, are structurally fragile and prone to rupture, leading to further plaque destabilization and expansion of the necrotic core. In advanced plaques, healed ruptures can be observed microscopically, where disruption of the fibrous cap can be seen with characteristic changes in collagen and proteoglycan deposition. Healed ruptures often reveal a mixture of collagen, proteoglycans, and inflammatory cell infiltration, which represent the body's attempt to repair the rupture. However, this repair process often fails to restore the plaque to a stable state, leaving it prone to future rupture.

Plaque Erosion

In addition to plaque rupture, another mechanism of thrombosis formation is plaque erosion. This occurs when the endothelium overlying the plaque is damaged, exposing the intima without the fibrous cap rupture. Unlike plaque rupture, plaque erosion is typically characterized by minimal inflammation and a smooth muscle cell-rich intima that lacks the fibrous cap. The thrombus formed in this case is often less stable than those formed after rupture, but it can still lead to acute coronary events such as myocardial infarction. Studies have shown that around 40% of patients who die from acute myocardial infarction (MI) exhibit plaque erosion rather than rupture. Plaque erosion typically involves fewer macrophages and T lymphocytes compared to rupture, and calcification is less commonly observed. Additionally, patients with plaque erosion often have elevated levels of myeloperoxidase, a marker of acute inflammation, suggesting that macrophage-driven inflammation plays a role in the thrombotic process.

Gross Findings of Atherosclerotic Plaques

Gross findings of atherosclerotic plaques provide important insights into the stage and severity of the disease. Fatty streaks, the earliest form of atherosclerotic lesion, appear as bright yellow, minimally raised lesions that stain strongly with oil red O, indicating the presence of lipids. These lesions are typically present from an early age and represent the first stage of atherosclerosis. Over time, these fatty streaks evolve into fibrous plaques, which are firm, raised lesions that appear white or pale on gross examination. Fibrous plaques are composed primarily of collagen and smooth muscle cells and are relatively well-circumscribed. In advanced stages, plaques may ulcerate, resulting in the rupture of the fibrous cap and the formation of thrombosis. Ulcerated plaques are typically associated with a greater risk of cardiovascular events due to their propensity to cause sudden occlusion of blood vessels. In carotid plaques, as in coronary arteries, calcification is often observed, indicating more advanced disease. Notably, the development of fatty streaks and fibrous plaques occurs similarly in both men and women, although the rate of progression may differ based on various risk factors. The progression of atherosclerosis, particularly the development of vulnerable plaques characterized by thin fibrous caps, is a complex process driven by lipid accumulation, inflammation, and proteolytic degradation. The rupture of these plaques or their erosion can lead to catastrophic events such as myocardial infarction and stroke. Understanding the mechanisms behind plaque instability, including the role of macrophages, proteases, and microvessel dysregulation, is critical for developing targeted therapies to prevent these life-threatening complications. The clinical detection of vulnerable plaques through advanced imaging and biochemical markers is essential for identifying individuals at high risk and improving preventive strategies.

History and Physical:

The history and physical examination are essential for diagnosing cardiovascular conditions associated with atherosclerosis. Blood pressure measurement is crucial for assessing hypertension, a key risk factor for atherosclerosis. Peripheral pulses should be palpated to evaluate circulation and identify possible arterial blockages or occlusions. Listening for bruits, especially in the carotids and abdomen, helps detect turbulent blood flow, often indicating stenosis or aneurysms. A pulsatile abdominal mass may suggest an abdominal aortic aneurysm, a common complication of atherosclerosis. Examination for signs of heart failure, such as jugular venous distention or pulmonary crackles, is important to assess the impact of advanced atherosclerosis on cardiac function. Additionally, the presence of xanthomas, fatty deposits on the skin, may indicate hyperlipidemia, which is often associated with the development of atherosclerotic plaques. These clinical findings, combined with a thorough history, guide the diagnosis and management of atherosclerosis and related cardiovascular diseases.

Evaluation:

The evaluation of atherosclerotic cardiovascular disease (ASCVD) involves several diagnostic tools and tests that assess both risk factors and existing disease burden. The initial approach to evaluation typically includes a comprehensive assessment of lipid profiles, blood glucose levels, and inflammatory markers.

Lipid Profile and Blood Glucose

Measuring LDL-cholesterol is fundamental to evaluating ASCVD risk, as elevated levels contribute to plaque formation in arterial walls. In addition, measuring plasma glucose is crucial for assessing the risk associated with diabetes mellitus, a significant factor in the development of ASCVD. High-sensitivity C-reactive protein (hsCRP) is another marker that can be evaluated in certain patients. This test helps to assess systemic inflammation, which plays a role in atherosclerotic plaque instability and rupture, leading to adverse cardiovascular events.

Screening for Abdominal Aneurysm

Abdominal ultrasound is indicated in older individuals, especially those with multiple ASCVD risk factors. This test is particularly important for detecting abdominal aortic aneurysms (AAA), a potential complication of advanced atherosclerosis. Early detection of an AAA can guide management and prevent life-threatening rupture.

Peripheral Artery Disease (PAD) Screening

Peripheral artery disease is closely linked with ASCVD, as it reflects generalized atherosclerotic involvement in peripheral arteries. Screening for PAD typically involves the measurement of the ankle-brachial index (ABI) using a Doppler device. A normal ABI is between 1.0 and 1.4, and values below 0.9 suggest the presence of PAD. The test is non-invasive, cost-effective, and valuable for identifying PAD early, which can be a marker for other systemic atherosclerotic conditions, such as coronary artery disease (CAD) and cerebrovascular disease.

Carotid Artery Sonography

Carotid artery sonography is used when there is suspicion of carotid stenosis, especially in patients with a carotid bruit (an abnormal sound heard during auscultation, often indicating turbulent blood flow caused by stenosis). This test is essential for identifying significant blockages in the carotid arteries, which can lead to ischemic stroke if untreated.

Electrocardiogram (ECG) and Stress Testing

An ECG is a basic diagnostic tool for evaluating the electrical activity of the heart. It can detect arrhythmias and other abnormalities, but in the context of ASCVD, a stress ECG is more useful. This test assesses how the heart responds to physical stress and can reveal signs of ischemia (reduced blood flow), which is indicative of underlying coronary artery disease (CAD).

Calcium Scoring by Electron Beam Computed Tomography (EBCT)

Electron beam computed tomography (EBCT) is increasingly used to assess coronary artery disease. The calcium score derived from EBCT measures the amount of calcified plaque in the coronary arteries. It is particularly useful for assessing plaque burden and helps to estimate the patient's risk of future cardiovascular events. The interpretation of calcium scoring should be age-adjusted, as plaque formation increases with age.

Angiography

Coronary angiography remains the gold standard for imaging atherosclerotic lesions in coronary arteries. It allows for detailed visualization of arterial blockages and provides an accurate assessment of coronary circulation. However, angiography is invasive and is typically reserved for high-risk patients or those with symptoms such as chest pain, suggesting active disease. It is not used for routine screening.

Non-invasive Imaging: CT and Cardiac MRI

For non-invasive evaluation, computed tomography (CT) angiography has emerged as a promising option for detecting coronary artery disease. CT angiography allows for the visualization of coronary arteries and is capable of identifying low-attenuated plaques that are often prone to rupture. This imaging technique is also predictive of future acute coronary events, making it a valuable tool in assessing a patient’s risk profile. Along with CT angiography, cardiovascular magnetic resonance imaging (cardiac MRI) offers high-resolution images of the heart and vessels and may be useful in specific patient populations, particularly those with complex atherosclerotic disease. However, both techniques have limitations, primarily their cost and the need for specialized equipment and expertise. In summary, the evaluation of ASCVD involves a combination of clinical assessments and diagnostic tests. These include lipid profiles, blood glucose measurements, imaging for abdominal aortic aneurysm and carotid stenosis, as well as the use of non-invasive tests like ABI and advanced imaging techniques such as CT and cardiac MRI. Angiography remains the gold standard for diagnosing CAD but is reserved for high-risk patients. While newer imaging technologies show promise, cost remains a significant factor in their widespread use. Proper selection of tests based on patient risk factors and clinical presentation ensures a more accurate diagnosis and better management of ASCVD.

Treatment and Management:

The treatment and management of atherosclerotic cardiovascular disease (ASCVD) primarily focus on addressing modifiable risk factors such as elevated LDL cholesterol (LDL-C), high blood pressure (BP), diabetes, and unhealthy lifestyle choices. Effective management includes a combination of pharmacological interventions, lifestyle modifications, and, in certain cases, surgical procedures.

Lifestyle Modifications

The foundation of ASCVD management begins with lifestyle changes. Patients should be encouraged to engage in regular physical activity, aiming for 90 to 150 minutes of moderate-intensity exercise per week. A healthy diet is critical, with a focus on reducing saturated fats (found in red and processed meats, organ meats) and trans fats (present in baked goods). Salt intake should be limited to less than 5 grams per day, while increasing the intake of fiber, monounsaturated fats (found in olive oil and nuts), fatty fish (such as salmon), and a variety of fruits and vegetables. Smoking cessation is another essential component of treatment, and patients should be referred to smoking cessation programs to improve long-term cardiovascular health.

Pharmacological Treatment

The use of statins, or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, is the cornerstone of managing elevated LDL-C levels. Statins not only lower LDL-C but also reduce the risk of cardiovascular events and mortality. Statin therapy is usually initiated in individuals with elevated cholesterol levels or those at high risk of ASCVD. For managing blood pressure, a multi-drug approach is often necessary. A combination of drugs from different classes, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), diuretics, beta-blockers, and calcium channel blockers (CCBs), may be required to achieve optimal BP control. The target BP for patients with ASCVD or at high risk is generally below 130/85 mmHg. Adequate BP control is essential to prevent complications such as stroke. In managing diabetes, a multifaceted approach is necessary, including medications, diet, and lifestyle modifications. The goal is to maintain glycated hemoglobin (HbA1c) levels below 7%, in addition to keeping BP below 130/85 mmHg and LDL-C below 100 mg/dL, particularly for those with primary prevention.

Revascularization and Thrombolysis

For patients with established clinical ASCVD, revascularization procedures such as percutaneous coronary intervention (PCI) (angioplasty), coronary artery bypass grafting (CABG), and other procedures may be necessary. These procedures are performed to restore blood flow to the heart or other affected regions, particularly in patients with severe blockages or symptoms. In cases of acute events such as a stroke (cerebrovascular accident, CVA) or acute limb ischemia due to thrombus or embolus, thrombolysis or clot-dissolving medications may be used to restore circulation. In summary, the management of ASCVD involves controlling risk factors through a combination of lifestyle changes and pharmacologic interventions. Statins, antihypertensive drugs, and diabetes management therapies are central to reducing the burden of ASCVD. In certain clinical scenarios, revascularization and thrombolytic therapy are essential to alleviate symptoms and prevent adverse cardiovascular events.

Differential Diagnosis

The differential diagnosis of atherosclerotic cardiovascular disease (ASCVD) includes a wide range of potential conditions, as its symptoms can overlap with those of various other diseases. ASCVD can manifest in different ways, such as chest pain, dizziness, claudication (pain or cramping in the legs due to inadequate blood flow), and generalized weakness. Given the broad spectrum of symptoms that ASCVD shares with other health issues, a thorough patient history and physical examination, along with targeted diagnostic tests, are crucial to differentiating ASCVD from other conditions that may present similar symptoms. Accurate and early detection relies on identifying these signs and ruling out other possible causes, ensuring the proper diagnosis and treatment plan [15][16].

Prognosis:

The outlook for individuals with ASCVD has improved significantly due to advancements in the management of its key risk factors, including elevated LDL cholesterol (LDL-C) through the use of statins, blood pressure (BP) control, diabetes management, smoking cessation, regular physical activity, and maintaining a balanced, healthy diet. With appropriate treatment and adherence to these lifestyle modifications, the prognosis for those with ASCVD is generally favorable. However, the prognosis becomes more unfavorable when the disease progresses to end-organ damage, leading to severe complications. These complications may include heart failure, ischemic stroke with subsequent paralysis and cognitive impairment, gangrene resulting in amputations, and the rupture of an abdominal aneurysm, all of which represent severe stages of the disease that are more difficult to manage [15][16].

Complications:

ASCVD can manifest in several serious forms, including coronary artery disease (CAD), cerebrovascular disease (CVD), transient ischemic attacks (TIA), peripheral artery disease (PAD), abdominal aneurysms, and renal artery stenosis, especially in male patients. These conditions represent some of the more common complications associated with ASCVD. Although this article focuses primarily on the management of ASCVD risk factors and tests for assessing these complications, further in-depth discussion of each specific complication is beyond its scope. The details regarding the treatment and management of these complications are addressed in other specialized chapters within this series, providing a more comprehensive understanding of how these conditions should be approached in clinical practice [15][16].

Enhancing Healthcare Team Outcomes:

Atherosclerosis, along with its associated pathologies, is largely preventable through proactive health management. Healthcare providers play a vital role in educating patients about the importance of preventive measures. These include encouraging regular physical exercise, smoking cessation, achieving and maintaining a healthy body weight, eating a balanced diet, and ensuring adherence to prescribed medications, particularly those aimed at lowering lipid levels. The evidence supporting these preventive strategies is substantial, showing that when implemented effectively, they can significantly reduce the risk of major cardiovascular events and strokes. As such, healthcare workers are instrumental in helping patients adopt these lifestyle changes, which can have a substantial impact on long-term health outcomes [15][16].

Conclusion:

Atherosclerosis remains a leading cause of morbidity and mortality worldwide, underscoring the need for a comprehensive understanding of its pathophysiology, risk factors, and management strategies. This review highlights the critical role of lipid accumulation, inflammation, and endothelial dysfunction in the initiation and progression of atherosclerotic plaques. The disease progresses through distinct stages, from early fatty streaks to advanced plaques that are prone to rupture or erosion, leading to acute cardiovascular events such as myocardial infarction and stroke. Understanding these mechanisms is essential for developing targeted therapies and preventive measures. The review emphasizes the importance of early detection and risk stratification using advanced diagnostic tools, including lipid profiling, imaging techniques like CT angiography, and biomarkers such as high-sensitivity C-reactive protein (hsCRP). These tools enable healthcare providers to identify high-risk individuals and implement timely interventions. Lifestyle modifications, including regular physical activity, a heart-healthy diet, and smoking cessation, form the cornerstone of atherosclerosis management. Pharmacological interventions, particularly statins for lowering LDL cholesterol and antihypertensive agents for blood pressure control, have proven effective in reducing the risk of cardiovascular events. Despite significant advancements in treatment, challenges remain, particularly in managing advanced disease with end-organ damage. Complications such as heart failure, ischemic stroke, and peripheral artery disease require specialized care and often surgical interventions. The prognosis for patients with atherosclerosis has improved with early and aggressive management of risk factors, but the disease remains a significant burden on healthcare systems globally. Healthcare providers play a pivotal role in educating patients about preventive measures and ensuring adherence to treatment plans. Multidisciplinary approaches involving primary care physicians, cardiologists, dietitians, and other specialists are essential for optimizing patient outcomes. Future research should focus on unraveling the molecular mechanisms of atherosclerosis, developing novel therapeutic targets, and improving non-invasive diagnostic techniques to further reduce the global burden of this disease. In conclusion, atherosclerosis is a preventable and manageable condition with timely intervention. By addressing modifiable risk factors and leveraging advancements in diagnostics and treatment, healthcare providers can significantly improve the quality of life for patients and reduce the incidence of life-threatening cardiovascular events.

References:

1. Dichgans M, Pulit SL, Rosand J. Stroke genetics: discovery, biology, and clinical applications. Lancet Neurol. 2019 Jun;18(6):587-599.
2. Mohd Nor NS, Al-Khateeb AM, Chua YA, Mohd Kasim NA, Mohd Nawawi H. Heterozygous familial hypercholesterolaemia in a pair of identical twins: a case report and updated review. BMC Pediatr. 2019 Apr 11;19(1):106.
3. Paul S, Lancaster GI, Meikle PJ. Plasmalogens: A potential therapeutic target for neurodegenerative and cardiometabolic disease. Prog Lipid Res. 2019 Apr;74:186-195.
4. Reiss AB, Grossfeld D, Kasselman LJ, Renna HA, Vernice NA, Drewes W, Konig J, Carsons SE, DeLeon J. Adenosine and the Cardiovascular System. Am J Cardiovasc Drugs. 2019 Oct;19(5):449-464.
5. Shafi S, Ansari HR, Bahitham W, Aouabdi S. The Impact of Natural Antioxidants on the Regenerative Potential of Vascular Cells. Front Cardiovasc Med. 2019;6:28.
6. Doodnauth SA, Grinstein S, Maxson ME. Constitutive and stimulated macropinocytosis in macrophages: roles in immunity and in the pathogenesis of atherosclerosis. Philos Trans R Soc Lond B Biol Sci. 2019 Feb 04;374(1765):20180147.
7. Ala-Korpela M. The culprit is the carrier, not the loads: cholesterol, triglycerides and apolipoprotein B in atherosclerosis and coronary heart disease. Int J Epidemiol. 2019 Oct 01;48(5):1389-1392.
8. Watson M, Dardari Z, Kianoush S, Hall ME, DeFilippis AP, Keith RJ, Benjamin EJ, Rodriguez CJ, Bhatnagar A, Lima JA, Butler J, Blaha MJ, Rifai MA. Relation Between Cigarette Smoking and Heart Failure (from the Multiethnic Study of Atherosclerosis). Am J Cardiol. 2019 Jun 15;123(12):1972-1977.
9. Whelton SP, Deal JA, Zikusoka M, Jacobson LP, Sarkar S, Palella FJ, Kingsley L, Budoff M, Witt MD, Brown TT, Post WS. Associations between lipids and subclinical coronary atherosclerosis. AIDS. 2019 May 01;33(6):1053-1061.
10. Carmona FD, López-Mejías R, Márquez A, Martín J, González-Gay MA. Genetic Basis of Vasculitides with Neurologic Involvement. Neurol Clin. 2019 May;37(2):219-234.
11. Perez-Martinez P, Katsiki N, Mikhailidis DP. The Role of n-3 Fatty Acids in Cardiovascular Disease: Back to the Future. Angiology. 2020 Jan;71(1):10-16.
12. Spannella F, Giulietti F, Di Pentima C, Sarzani R. Prevalence and Control of Dyslipidemia in Patients Referred for High Blood Pressure: The Disregarded "Double-Trouble" Lipid Profile in Overweight/Obese. Adv Ther. 2019 Jun;36(6):1426-1437.
13. Esper RJ, Nordaby RA. Cardiovascular events, diabetes and guidelines: the virtue of simplicity. Cardiovasc Diabetol. 2019 Mar 28;18(1):42.
14. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC, Virani SS, Williams KA, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report

of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Sep 10;140(11):e596-e646.
15. Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Karpov Y, Moryusef A, Pordy R, Prieto JC, Roe MT, White HD, Zeiher AM, Schwartz GG, Steg PG., ODYSSEY OUTCOMES Committees and Investigators. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019 Sep 03;74(9):1167-1176
16. Soohoo M, Moradi H, Obi Y, Rhee CM, Gosmanova EO, Molnar MZ, Kashyap ML, Gillen DL, Kovesdy CP, Kalantar-Zadeh K, Streja E. Statin Therapy Before Transition to End-Stage Renal Disease With Posttransition Outcomes. J Am Heart Assoc. 2019 Mar 19;8(6):e011869.
17. Pahwa, R., & Jialal, I. (2023). Atherosclerosis. In *StatPearls [Internet]*. StatPearls Publishing.

التصلب العصيدي: نظرة محدثة لمقدمي الرعاية الصحية

الملخص:

الخلفية: التصلب العصيدي هو مرض مزمن التهابي يصيب الشرايين، يتميز بتراكم الدهون والعمليات الالتهابية التي تؤدي إلى تكوّن اللويحات والأحداث القلبية الوعائية التالية مثل النوبات القلبية والسكتات الدماغية. يُعد التصلب العصيدي السبب الرئيسي للوفاة في المجتمعات الصناعية، حيث يمثل حوالي 50% من الوفيات. تشمل عوامل الخطر فرط الكوليسترول في الدم، ارتفاع ضغط الدم، مرض السكري، التدخين، والعوامل المتعلقة بنمط الحياة مثل قلة النشاط البدني والنظام الغذائي غير الصحي. يتطور المرض من الخطوط الدهنية إلى اللويحات المتقدمة التي قد تتمزق أو تتآكل، مما يؤدي إلى أحداث قلبية وعائية حادة.

الهدف: تهدف هذه المراجعة إلى تقديم نظرة محدثة حول الفيزيولوجيا المرضية، وعوامل الخطر، والأساليب التشخيصية، واستراتيجيات العلاج للتصلب العصيدي، مع التأكيد على أهمية فهم آلياته الجزيئية والخلوية لتطوير تدخلات علاجية فعّالة.

الأساليب: تستعرض المراجعة المعرفة الحالية حول مسببات التصلب العصيدي، والوبائيات، والفيزيولوجيا المرضية. كما تناقش أدوات التشخيص مثل تحليل الدهون، وتقنيات التصوير (مثل تصوير الأوعية بواسطة الأشعة المقطعية، وتقييم الكالسيوم)، والتقييمات السريرية. كما يتم فحص استراتيجيات العلاج التي تشمل التعديلات في نمط الحياة، العلاجات الدوائية (مثل الستاتينات، والعلاج الخافض للضغط)، والتدخلات الجراحية (مثل إعادة التوعية).

النتائج: يتطور التصلب العصيدي على مراحل، من الخطوط الدهنية المبكرة إلى اللويحات المتقدمة المعرضة للتمزق. لقد أدت التقدمات التشخيصية مثل التصوير غير الجراحي والعلامات الحيوية إلى تحسين الكشف المبكر وتقسيم المخاطر. يشمل العلاج الفعّال السيطرة على عوامل الخطر القابلة للتعديل من خلال تغييرات نمط الحياة والعقاقير، مما يقلل بشكل كبير من خطر الأحداث القلبية الوعائية. ومع ذلك، يبقى علاج المرض المتقدم الذي يؤدي إلى تلف الأعضاء التحدي الأكبر.

الاستنتاج: يعد التصلب العصيدي مرضًا معقدًا ومتعدد العوامل يتطلب نهجًا شاملاً للوقاية والتشخيص والعلاج. يمكن أن تحسن التدخلات المبكرة من خلال تغييرات نمط الحياة والعلاج الدوائي بشكل كبير من النتائج. تظل الأبحاث المستمرة في الفيزيولوجيا المرضية وأدوات التشخيص المبتكرة أساسية للحد بشكل أكبر من عبء مرض التصلب العصيدي القلبي الوعائي على مستوى العالم.

الكلمات المفتاحية: التصلب العصيدي، أمراض القلب والأوعية الدموية، تمزق اللويحات، كوليسترول LDL ، الالتهاب، الستاتينات، التصوير، عوامل الخطر، العلاج.